Skip to main content
. 2021 May 31;11:683341. doi: 10.3389/fonc.2021.683341

Figure 2.

Figure 2

Kaplan-Meier survival curves of treatment outcome including (A) overall survival (OS) and (B) time to progression (TTP) between Nivolumab group and Regorafenib group. The comparison of OS and TTP in both groups was not different.